Scienmag

OCTOBER 2, 2020

Credit: Virginia Tech Renowned tick immunobiologist Utpal Pal wants to ad apt the rabies vaccination platform to produce antibodies that can protect against Borrelia burgdorferi, the bacteria responsible for Lyme disease. The intention is to apply this work to other tick-borne diseases in the future.

Vaccination 88

Vaccination Vaccine Bacteria Development 88

Roots Analysis

FEBRUARY 27, 2024

What are Affimers : Affimers are small proteins that target and bind molecules on cellular surfaces in a manner analogous to monoclonal antibodies. In nature, they are made by a group of bacteria known as actinomycetes. The key difference is that affimers are optimized to enhance their structural stability.

Antibody 52

Antibody Licensing Licensing Contract Manufacturing 52

Pharmaceutical Technology

MARCH 10, 2023

Pharmaceutical and biotechnology industries widely use freeze-drying systems to protect vaccines, antibodies, antibiotics such as penicillin, blood plasma, proteins, enzymes, hormones, viruses, and bacteria from heat and minimise their biological activity.

Manufacturing 147

Manufacturing Production Containment Antibody 147

Delveinsight

NOVEMBER 26, 2020

Genmab discards antibody-drug conjugate after the early-phase fiasco. Genmab is ditching an antibody-drug conjugate after it flunked the mark in early-phase trials. The latter can usually resist Pseudomonas infections, but as they target a broad spectrum of bacteria, can also contribute to the increase of antibiotic-resistant bugs.

Antibody 79

Antibody Trials Drugs Engineer 79

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162

XTalks

JANUARY 6, 2021

Researchers at the National Institutes of Health (NIH) in the US have isolated small antibodies called “nanobodies” from a llama named Cormac that can block the SARS-CoV-2 coronavirus. Nanobodies are about a quarter of the size, and approximately one tenth of the weight, of a typical human antibody.

Antibody 105

Antibody Protein Bacteria In-Vitro 105

BioTech 365

OCTOBER 5, 2020

.–(BUSINESS WIRE)–The Gold Standard Diagnostics Group (GSD) today announced the immediate availability of their two new Lyme IgG and Lyme IgM EIA kits for detection of antibodies against Lyme disease causing bacteria. The two assays give laboratories a more … Continue reading →

Bacteria 40

Bacteria Antibody 40

XTalks

JULY 14, 2021

CDIs typically develop after the use of antibiotics, which can wipe out the gut’s healthy bacteria. Seres’ microbiome drug SER-109 aims to restore the healthy bacteria via an oral capsule that contains a protective species of gut bacteria. Difficile infection (CDI). Read the full articles here: .

Bacteria 52

Bacteria Marketing Drugs Containment 52

Scienmag

NOVEMBER 17, 2020

New research published in Arthritis & Rheumatology suggests that immune responses to certain bacteria that cause periodontal disease may play a role in patients’ higher cardiovascular disease risk. Among 197 patients with rheumatoid arthritis, those with antibody responses to common […].

Immune Response 40

Immune Response Bacteria Antibody Research 40

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Vaccination 130

Vaccination Vaccine Containment Immune Response 130

XTalks

JULY 25, 2023

The bacteria usually enter the body through wounds, but infection can also occur through contaminated meat or inhalation of spores. Cyfendus functions by stimulating the production of antibodies targeted against the protective antigen protein. Anthrax is a rare, yet severe disease caused by the bacterium B. Overall, 66.3

FDA Approval 98

FDA Approval Vaccination Vaccine Antibody 98

The Pharma Data

APRIL 22, 2023

Plasma cells produce antibodies that protect the body from invasive foreign substances, such as bacteria and viruses. In recent years, there has also been an increase in the use of anti-CD38 antibodies in combination with immunomodulatory agents or proteasome inhibitors for the initial treatment or at the first relapse.

Antibody 40

Antibody Protein Bacteria Drugs 40

pharmaphorum

DECEMBER 15, 2020

Globally, 15-25% of women are colonised with GBS, and they run the risk of transmitting the bacteria to their child in utero, during birth and / or during their first months of life. Phase 1 data from 300 healthy females have so far shown a favourable safety profile, while generating high levels of long-lasting antibodies.

Bacteria 52

Bacteria Vaccination Vaccine Immune Response 52

XTalks

AUGUST 2, 2022

Benlysta (belimumab) is a biologic therapy, a human monoclonal antibody. Autoreactive B cells release antibodies like other B cells do, except they release autoantibodies. The autoantibodies do not fight actual infection or bacteria, but rather the normal tissue in the body. How Benlysta (belimumab) Works.

FDA Approval 94

FDA Approval Antibody Bacteria Protein 94

Drug Discovery World

JANUARY 12, 2024

The top stories: Excitement over new antibiotics that can kill drug-resistant bacteria A novel antibiotic class targeting a major global pathogen and threat to human health has been discovered by scientists from Roche and Harvard University (Cambridge, MA, US).

Drugs 52

Drugs Immune Response Allergies Bacteria 52

The Pharma Data

MARCH 8, 2021

OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick. The main safety and immunogenicity readout (Primary Endpoint analysis) will be at Month 7, where peak antibody titers are expected. VLA15 has demonstrated strong immunogenicity and safety data in pre-clinical and clinical studies so far.

Vaccination 52

Vaccination Vaccine Bacteria Protein 52

Drug Discovery World

MAY 4, 2023

New research in mice has identified how gut bacteria alter the body’s response to PD-1 checkpoint blockade immunotherapy, currently used for the treatment of 25 forms of cancer. Such treatments could supplement or be an alternative to traditional antibody-based cancer immunotherapy.

Bacteria 52

Bacteria Research Medicine Antibody 52

The Pharma Data

SEPTEMBER 30, 2021

Nirsevimab is being developed by Sanofi and AstraZeneca and is being evaluated because the first investigational long-acting antibody designed to assist prevent lower tract infection (LRTI) caused by RSV altogether infants from birth up to 12 months aged during their first RSV season. In the U.S., About MenQuadfi In the U.S.,

Vaccination 52

Vaccination Vaccine Research Antibody 52

pharmaphorum

SEPTEMBER 28, 2021

New phase 2 data with their VLA15 vaccine shows that antibody responses from an initial three-dose regimen are initially high, although they start to decline after 18 months in adult subjects.

Vaccination 105

Vaccination Vaccine Bacteria Protein 105

Drug Discovery World

MARCH 14, 2023

For the first time, researchers have developed an mRNA vaccine that is 100% effective against a type of bacteria that is lethal to humans, paving the way for effective vaccination against antibiotic-resistant bacteria. However, until now scientists believed that mRNA vaccines against bacteria were biologically undoable.

Bacteria 59

Bacteria Vaccination Vaccine Protein 59

pharmaphorum

AUGUST 7, 2020

LRRK2 regulates lysosomes, which play a vital role in cell function by breaking down excess or worn-out cell parts, and can also destroy invading viruses and bacteria. Mutations in the LRRK2 gene can cause Parkinson’s disease.

Bacteria 68

Bacteria Marketing Licensing Licensing 68

The Pharma Data

JUNE 30, 2021

In our study, we measured the humoral response – so the level of antibodies – in naturally exposed cats,” relays Yasmin Parr. To achieve this, she developed a novel ELISA (Enzyme-linked Immunosorbent Assay) to measure a certain antibody type directed towards a specific protein of the virus.

Scientist 52

Scientist Immune Response Antibody Development 52

The Pharma Data

APRIL 26, 2022

This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.

Vaccination 52

Vaccination Vaccine Bacteria Protein 52

The Pharma Data

JULY 21, 2021

This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi , the bacteria that cause Lyme disease. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.

Vaccination 52

Vaccination Vaccine Trials Bacteria 52

The Pharma Data

DECEMBER 31, 2020

Previous studies have raised concern that COVID-19 patients might lose their immunity quickly once they recover, because the first wave of coronavirus antibodies tends to wane after the first few months. THURSDAY, Dec. Memory B cells specific to COVID-19 were found in samples taken 242 days after symptom onset, the results showed.

Vaccination 52

Vaccination Vaccine Antibody Immune Response 52

Drug Discovery World

DECEMBER 14, 2023

In November 2023, University of Glasgow and University of Oxford spin-out Glox Therapeutics raised £4.3M ($5.2M) in seed funding to develop targeted therapeutics against antibiotic-resistant Gram-negative bacteria. Another BioCity tenant, BioAscent provides science-led integrated drug discovery services.

Drugs 75

Drugs Life Science Research Scientist 75

The Pharma Data

DECEMBER 31, 2020

Antibodies Respond Differently to Severe Versus Mild COVID-19. Researchers at Stanford Medicine found that COVID-19 antibodies preferentially target different parts of the SARS-CoV-2 virus in mild COVID-19 cases than they do in severe cases. People with severe COVID-19 have low proportions of antibodies that target the spike protein.

Antibody 52

Antibody Research Bacteria Genetics 52

The Pharma Data

MARCH 13, 2022

CD8+ T cells are nicknamed killer T cells (they’re also known as cytotoxic T cells) for their ability to eliminate foreign invaders such as bacteria and viruses from the body. The team’s study was published March 1, 2022, in mBio, a journal from the American Society for Microbiology.

Immune Response 52

Immune Response Protein Medicine Genetics 52

pharmaphorum

OCTOBER 27, 2021

There was bad news for Lilly elsewhere is its Alzheimer’s pipeline as it announced the demise of anti-tau protein antibody zagotenemab, which had reached phase 2 but failed to have an impact on its primary endpoint. Cortexyme trial disappoints.

Trials 52

Trials Drugs Sales Bacteria 52

Drug Discovery World

OCTOBER 13, 2022

There was a selection of the technologies we will present including cell-based assays, ion indicator dyes, inhibitors, pharmacokinetic assays, bioisimilars, assay development antibodies, conjugation particles and other reagents for your drug discovery and development pipeline. .

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52

The Pharma Data

OCTOBER 26, 2020

AR-711 is a fully human immunoglobulin 1, or IgG1, monoclonal antibody discovered from screening the antibody secreting B-cells of convalescent COVID-19 patients. He will address the preclinical performance of AR-711, the advantages of direct lung delivery using nebulized aerosols, and the COVID-19 clinical program. About AR-711.

Antibody 52

Antibody Genetic Engineering Development Clinical Trials 52

XTalks

JANUARY 20, 2021

Ovalbumin led to increased dietary-antigen-specific IgE antibodies in the mice that were limited to the intestine. The researchers pieced together the events and were able to link the observed upregulation of IgE antibodies, activation of mast cells and histamine release to ingestion of the ovalbumin to an increase visceral pain.

Immune Response 52

Immune Response Research Allergies Protein 52

Pfizer

FEBRUARY 16, 2023

This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease. OspA is a surface protein expressed by the bacteria when present in a tick. FDA in July 2017.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

The Pharma Data

DECEMBER 13, 2020

Both patients experienced disease progression on immunotherapy with anti- PD-1/PDL-1 antibodies prior to enrollment in the study. . Evidence of durable stable disease was observed in two patients being treated for metastatic melanoma and metastatic small cell lung cancer. Sokolovska, A.,

Immune Response 40

Immune Response Engineer Clinical Trials Clinical Trials 40

The Pharma Data

OCTOBER 19, 2020

Diagnostics Update : To-date the FDA has authorized 282 individual EUAs, which include 220 molecular tests, 56 antibody tests and 6 antigen tests. . In a challenge trial, people are given a vaccine then intentionally dosed with the virus or bacteria that causes the disease. Diagnostics.

Vaccination 52

Vaccination Vaccine Trials Clinical Trials 52

The Pharma Data

OCTOBER 19, 2020

Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies. There are more than 90 different types of pneumococcal bacteria which can affect adults differently than children. Food and Drug Administration before the end of the year, remain on track.

Vaccination 52

Vaccination Vaccine Immune Response Containment 52

Drug Discovery World

APRIL 25, 2024

Grand View Research states that the market for cell lines is currently bolstered by the fact that the majority of biopharma companies use cell lines to synthesise recombinant monoclonal antibodies and proteins. There are a lot of considerations to take when choosing a cell line.

Development 59

Development Protein In-Vivo Life Science 59